Summary:
A randomized, parallel-group, 24 week, double-blind, placebo-controlled, multicenter Phase 3 study to assess the efficacy and safety of secukinumab compared to placebo in adult patients with active rotator cuff tendinopathy
Qualified Participants Must:
• 18-65 years old
• Unilateral rotator cuff tendinopathy for less than 6 months
Qualified Participants May Receive:
- Compensation for time and travel
- Study-related care at no cost